Our full interview with Varda CEO
@WillBruey at the
@NYSE on the company's $251M Series D and being a space, biotech, and defense biz.
“We now have drugs that are required to get to market via microgravity. And when that happens, what’s fascinating is now we have a perpetual demand for launch."
"And so, I think that is like the inflection point where industry has gone from confined to our home planet to slightly off our home planet in orbit."
"And I think that’s the most exciting thing to me. To me, that’s on the scale of when life went from sea to land."
"So my goal is to be like Muddy the Mudskipper, the first fish that went from sea to land."
"It was ugly. It was not beautiful. It was not glorious. He’s flopping around in the mud."
"And that’s kind of what we’re doing. We’re just shipping bioreactors to space and back. But that is literally the epic transition.”
We covered:
0:49 $251M Series D
1:51 Varda’s two business lines
1:55 Microgravity drugs
5:12 Changes since Series C
5:58 United Therapeutics
7:45 AI as an accelerant
9:01 Investors view
9:58 Modeling revenue
11:21 Hypersonic testing
14:02 Delivery from orbit
16:26 Heat shield
18:36 Vehicles 8 and 9
With
@itsmoislam and
@VardaSpace